ERBB2 and breast cancer: Indeed, the clinical success of ADCs has been demonstrated with FDA-approved ADCs for the treatment of patients with Hodgkin lymphoma (Adcetris®)5, 6, HER2-positive breast cancer (Kadcyla®)7, 8, acute lymphoblastic lymphoma (Besponsa®)9, and acute myeloid lymphoma (Mylotarg®)10 and more than 60 promising ADCs in clinical trials11, 12.